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Implanon NXT, a single-rod subdermal contraceptive implant, is one 
of the most effective contraceptive methods available.[1] As a long-
acting reversible contraceptive (LARC), it is not dependent on user 
adherence for effectiveness.[2] High levels of uptake and acceptability 
have been reported worldwide.[3,4] The implant was introduced into 
the South African (SA) national contraception programme in early 
2014, aiming to expand the contraceptive method mix and increase 
access to LARCs.[5] In the Demographic and Health Survey 2016, 
about 4% of sexually active women in the country were using the 
implant.[6] 
As with the introduction of any new contraceptive method into 
a national programme, it is critical to evaluate the experiences 
and perspectives of users in the early years after its introduction.[7] 
This evaluation was especially pressing given mounting concerns 
in the media and among healthcare providers in SA around the 
performance of implant services and declines in uptake.[8] Using a 
mixed-methods approach, we conducted a survey of implant users in 
two districts of SA. This study, one component of a larger evaluation 
of the implant programme, sought to identify shortcomings in the 
current services, and the steps required to improve users’ experiences.
Methods 
Participant recruitment
We selected 12 primary healthcare facilities providing contraceptive 
services: six in the City of Johannesburg, Gauteng Province, and six 
in North West Province. The methods used to select the facilities and 
the results of other components of the evaluation have been detailed 
elsewhere.[9,10] We extracted contact details of women aged >18 years 
who had had an implant inserted since 2014 (n=751). In total, 262 
of these women agreed to be interviewed, with the remainder either 
not contactable (telephone number not recorded or invalid), or not 
willing to participate. Owing to difficulties in finding a mutually 
convenient time for interview, or because a woman did not attend a 
scheduled appointment, only 152 of these women were interviewed 
(20% of the potentially eligible 751). A fieldworker conducted semi-
structured interviews face-to-face between June and November 2016. 
The interviews were held at the facility where the woman had had the 
implant inserted (Gauteng n=93, North West n=59).
The study was approved by the University of the Witwatersrand 
Human Research Ethics Committee (ref. no. M151147), and 
permission for the study was granted by the District Research 
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Background. Implanon NXT, a long-acting reversible contraceptive, was introduced in South Africa (SA) in early 2014, aiming to expand 
the method mix and increase its effectiveness. Initial uptake was high, but has since declined considerably. In these early years after the 
implant’s introduction, it is important to identify reasons for the decline, and remedy gaps in services. 
Objectives. To determine periods of use, reasons for the use and early removal of the implant Implanon NXT.
Methods. In 2016, we recruited 152 women from six clinics in the City of Johannesburg, and six in North West Province, SA. A semi-
structured interview was administered to 91 women currently using the implant and 61 previous users. We examined user perspectives, 
factors influencing women’s experiences with the implant and reasons for discontinuation.
Results. The participants’ mean age was 30 years, with only 15% aged <25. Implant uptake was motivated by convenience (less frequent 
visits required than for short-acting methods) and by favourable views of the method among friends, family and healthcare providers. Only 
about a quarter of women recalled being counselled pre-insertion about implant effectiveness, and half about side-effects pre-insertion. 
Among discontinuers, the median time to device removal was 8 months (interquartile range 6 - 12), and this was primarily as a result of side-
effects (90%), especially bleeding-pattern changes and headaches. Removals were most common among married and cohabiting women, 
often ascribed to the effects of bleeding on their sexual relationships. Rumours and misinformation contributed to some removals. Overall, 
women’s experiences with the implant were rated ‘good’ or ‘very good’ by 74% of those continuing use, many of whom reported not having 
experienced any side-effects or that these had diminished over time. 
Conclusion. Levels of acceptability among continuing users were high, mainly linked to the method’s convenience. While early favourable 
views drove uptake, negative perceptions, if unaddressed, may now undermine services. Deficiencies in counselling around effectiveness 
and side-effects may extend to contraceptive services more generally. Women require more intensive support when experiencing side-
effects, including effective systematic approaches to ameliorating bleeding and headaches. Implant services could specifically target young 
women and first-time contraceptive users. These actions together could reverse the persistent decline in implant use in SA. 
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Committee of the City of Johannesburg (ref. no. 2015-16/048), and 
provincial ethics committee of the North West Province Department 
of Health (ref. no. NW_2015RP29_838). All participants provided 
written informed consent, and were reimbursed ZAR50 (~USD4) for 
their transport expenses. 
Study tools and data analysis 
We collected data on women’s sociodemographic, reproductive and 
contraceptive history, motivations for implant use, partner negotiation 
around use, counselling received, duration of implant use and 
experiences with the method. Women were asked if they knew how 
the implant works to prevent pregnancy, and for how long the implant 
could be used. Those who had removed the implant were questioned 
about the timing of the removal, reasons for discontinuing the method 
and subsequent contraception use. Overall experiences of the implant 
were assessed using a 5-point Likert scale ranging from ‘very bad’ to 
‘very good’, and by asking women whether they thought the implant 
was better or worse than a range of other contraceptive methods. 
Women were asked several open-ended questions, enabling them to 
narrate their experiences in their own words. For example, women 
were requested to explain the rating they had given when they had 
scored the implant on the Likert scale. Data collectors captured 
women’s free text responses on the questionnaire. In some instances, a 
categorical variable was derived by categorising the free-text responses 
based on common themes identified in the text. 
In our analysis, we sought to describe women’s experiences and to 
contrast the perspectives of women who had continued implant use 
(‘users’) with those who had removed it (‘removers’), drawing on a 
World Health Organization analytical framework.[11] To determine 
whether the characteristics and perspectives of users and removers 
differed, we used χ2 tests to compare categorical variables, and 
Student’s t-tests or Wilcoxon rank sum tests for continuous variables, 
as appropriate. We then examined the full text responses, and used 
them to contextualise and interpret the quantitative data. Participant 
quotes were selected to illustrate key findings. 
Results 
Users (n=91) had inserted the implant a median 24 months ago, while 
removers (n=61) had used the implant for a median 8 months, with 
60% removing the implant less than a year after insertion. Only 33% 
(20/61) removed the implant at the same facility where it had been 
inserted. Sixteen percent (10/61) of removals were performed by a 
doctor in the private sector. 
Sociodemographic characteristics and contraceptive 
history
The mean age of both groups was 30 years (Table 1), with 15% 
(23/152) between ages 18 and 25. About 80% were SA citizens, with the 
remainder mostly from neighbouring Zimbabwe (14%). Around 60% 
of the women were employed, two-thirds (66% user, 67% remover) had 
completed secondary schooling and a further quarter (29% user, 26% 
remover) had some form of tertiary qualification. Half of the women 
(74/148) said they did not know their HIV status, and this was similar 
in both groups. 
While many characteristics of users and removers were similar, some 
important differences were noted. Removers were much more likely to 
be currently sexually active than users (92% v. 80%; p=0.06). Compared 
with users, removers were more likely to live with their partners (22% v. 
46%; p=0.002), and to be married (34% v. 22%; p=0.05). 
In both groups, for 13% of women, the implant was the first 
contraceptive method that they had used, aside from condoms. 
Previous use of an intrauterine device (IUD), another LARC, 
was negligible among all women, and only 28% of healthcare 
providers mentioned this as an option for women post-removal, 
only two of whom took up the offer. At the time of interview, 77% 
of the removers were using another contraceptive, mainly depot 
medroxyprogesterone acetate (DMPA) (36%) or the oral pill (26%). 
Male condoms were being used by 38% of removers (23/61), half of 
whom were using condoms as their sole contraceptive (11/23).
Factors influencing implant uptake 
The majority (55%) of participants had first heard about the implant 
by word of mouth from friends, family and other implant users (Table 2). 
One woman explained how a family member had influenced her decision-
making: ‘I was interested on it when my younger sister told me about 
it.’ Friends had also helped assuage women’s fears about the method: 
‘At first I was scared that they gonna put something in my arm, but my 
friend told me it was not painful, so I went for it.’ One 18-year old stated 
that her mother had made the decision: ‘I didn't decide to use it, my 
mom said I must use it, she accompanied me to the clinic’. 
About 90% each of users and removers said that they had 
themselves gone to the clinic to request that the implant be inserted, 
rather than the method being suggested to them by a provider during 
a routine visit. About a quarter of women (30% user, 25% remover) 
had, however, previously heard of the method from a provider, who 
in some instances appeared to have swayed women’s choices: ‘The 
nurses kept teaching us about it and recommending it, so that’s why 
I tried it.’ Of note is that only 7% (11/152) of women mentioned 
publicity materials at clinics or schools, or on the internet and 
television, as sources of information, although one participant did say 
that she had heard of the implant ‘from the television; Dr Motsoaledi 
[the minister of health] was explaining about it’. 
The primary motivation for choosing the implant was convenience, 
because the long duration of pregnancy protection meant that 
frequent clinic visits were not required and women would not have 
to remember daily pill-taking (46% of users and 67% of removers; 
p=0.03). Reducing the number of visits was especially important for 
some women. One, aged 24, stated that she used the implant ‘because 
of the duration that it stays, [I have] enough time to complete my 
studies’. Similarly, another mentioned that ‘I just started working at 
that time [when the implant was inserted], so I couldn't afford to get 
leave days [for attending the clinic]’.
Overall, only 11% of users and 3% of removers mentioned 
contraceptive effectiveness as the main motivation for use (p=0.08). 
One of these, a 19-year-old HIV-positive woman, recounted that 
‘My mom said I must use it as I was sexual active, she thought it will 
be a good solution to prevent pregnancy’. Another 33-year-old user 
also explained: ‘I decided on implant because I didn't want to have 
unwanted pregnancy and the previous injection did not treat me well.’ 
As this suggests, use of the implant in some instances had been driven 
by dissatisfaction with other methods. Another respondent said: ‘The 
nurse told me about the method ’cos I was complaining about the Pill 
and how it made me feel.’
Women’s knowledge about the implant
Almost all the women knew that the implant could be used for 3 years 
(99%). In the free-text responses it was clear that counselling had 
strongly emphasised the notion that the implant ‘needs to’ or ‘should’ 
be used for that length of time. Many women, however, wondered 
whether the method was suitable for shorter time periods, for 
example, if they desired contraception for only 6 months. 
Seemingly, little information had been provided to participants 
about the effectiveness of the implant in preventing pregnancy. Only 
29% of users and 20% of removers recalled this being discussed 
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(p=0.19). Not surprisingly, therefore, some were concerned about the 
method’s efficacy: ‘I just want to know whether is there any chance 
to conceive if you were using implant.’ Conversely, a few women 
were worried about how long it would take for fertility to return after 
removal, if at all: ‘I just want to know if I will be able to conceive 
again.’ Only 34% of users and 23% of removers answered in the 
affirmative to the question: ‘Do you know how the implant works to 
prevent pregnancy?’ (p=0.12). 
When asked what additional information they require, women 
mostly wondered about how side-effects should be managed and 
why specific effects occur. One woman wanted to have a better 
understanding of the ‘body’s reaction to it [the implant]’, and another 
was concerned about whether ‘the side-effects [can] damage anything 
in my body’. Many women also wondered why only some had 
experienced side-effects and not others, with one asking: ‘Why do 
other people react badly and I haven't even had a single side-effect?’ 
Among both users and removers, only 57% of users and 52% of 
removers reported having been informed about side-effects of the 
implant at the time of insertion. 
Three women wanted more information about potential drug 
interactions with the implant, especially about the combined use of the 
implant and antiretroviral drugs. One woman wished to know where 
to go for removal, and another asked how this would actually be done.
Overall perspectives of women on the implant 
When asked to rate their overall experience with the implant, 74% of 
current users classified their experience as having been ‘good’ or ‘very 
good’, and the large majority felt the implant was superior to other 
methods. For example, 68% of users felt the implant was superior to 
injectable contraception. By contrast, 69% of removers viewed their 
Table 1. Demographic characteristics and contraception history, comparing women currently using the implant and those who 
have removed the device 
Variables
Implant users 
(N=91),
n (%) or mean (SD)
Implant removers 
(N=61),
n (%) or mean (SD) p-value
Province
Gauteng 63 (69) 30 (49) -
North West 28 (31) 31 (51) 0.01
Age (years), mean (SD) 30 (6) 30 (6) 0.35
Born in South Africa 73 (81) 48 (79) 0.71
Home language
Setswana 19 (20) 25 (41) -
isiZulu 26 (29) 7 (11) -
isiXhosa 10 (11) 7 (11) -
English 5 (5) 3 (5) -
Other 31 (34) 31 (19) 0.04
Employed 56 (62) 33 (54) 0.32
Household income, ZAR (USD)
Unknown 21 (26) 11 (19) -
<5 000 (357) 39 (48) 28 (49) -
5 000 - 9 999 (357 - 714) 18 (22) 14 (25) -
10 000 - 30 000 (714 - 2 142) 4 (5) 4 (7) 0.81
Highest level of education completed
Primary 5 (6) 4 (7) -
Secondary 59 (66) 41 (67) -
Post-school qualification 26 (29) 16 (26) 0.92
Currently in sexual relationship 72 (80) 54 (92) 0.06
Current relationship status*
Married 20 (22) 21 (34) -
Stable partner 28 (31) 25 (41) -
Casual partners 8 (9) 4 (7) -
Single 34 (38) 11 (18) 0.05
Lives with partner 20 (22) 28 (46) 0.002
Other contraceptives ever used†
DMPA 50 (55) 29 (48) 0.37
NET-EN 21 (23) 16 (26) 0.60
Oral pill 30 (33) 35 (57) 0.003
Intrauterine device 1 (1) 1 (2) 0.77
Male condoms 51 (56) 43 (70) 0.07
Female condoms 9 (10) 8 (13) 0.54
Female sterilisation 1 (1) 1 (2) 0.77
SD = standard deviation; DMPA = depot medroxyprogesterone acetate; NET-EN = norethisterone enanthate; USD1 = ZAR14 (at the time of the study).  
*Women self-identified as married or not. 
†Multiple-response question.
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experience with the method as having been ‘bad’ or ‘very bad’. Still, 
some 15% of removers felt their experience had been ‘good’, and a 
similar proportion believed that the implant was better than oral 
contraception and injectable methods. 
In describing their experiences with the implant, users mainly 
commented on the method’s convenience, mirroring the motives that 
had underlain their initial decision to use it. A 25-year-old described 
this as: ‘I don’t have to worry about coming to the clinic to collect 
Table 2. Initiation of the implant, duration of use and overall experiences with the method, comparing women currently using the 
implant and those who have removed the device 
Variable category Variable
Implant users 
(N=91),
n (%) or  
median (IQR)
Implant 
removers 
(N=61), n (%) or  
median (IQR) p-value
Initial source of information about  
the implant
Friend 27 (30) 18 (30) -
Family member 11 (12) 9 (15) -
Other implant user 12 (13) 6 (10) -
Clients at facility 6 (7) 7 (11) -
Provider at facility 27 (30) 15 (25) -
School 1 (1) 2 (3 ) -
Pamphlets or posters at clinics 0 (0) 3 (5 ) -
Television 3 (3) 0 (0) -
Internet 2 (2) 0 (0) 0.30
Discussed implant use with partner before 
insertion*
No, but knows it’s inserted 13 (16) 13 (24) -
No, does not know it’s inserted 27 (34) 7 (13) -
Yes, talked and agreed 37 (47) 35 (64) -
Yes, talked and did not agree 2 (3) 0 (0) 0.02
Request for implant User initiated 80 (90) 53 (91) -
Nurse initiated 9 (10) 5 (9) 0.76
Reasons method was initiated Saves time and fewer clinic visits† 29 (32) 22 (37) -
Longer duration of protection† 14 (16) 18 (30) -
For effective pregnancy prevention 10 (11) 2 (3) -
Better than other methods 7 (8) 3 (5) -
Recommended at facility 6 (7) 5 (8) -
Information from others 6 (7) 3 (5) -
Does not want more children 6 (7) 1 (2) -
Other 12 (13) 5 (8) 0.19
Information provided at initiation‡ Effectiveness of implant 27 (29) 12 (20) 0.19
How long implant can be used for 61 (67) 40 (66) 0.85
When to return for removal 46 (51) 34 (56) 0.53
Safety 37 (41) 12 (20) 0.007
Side-effects 52 (57) 32 (52) 0.57
How to know implant is in place 16 (18) 6 (10) 0.18
Preventing STIs 14 (15) 8 (13) 0.70
Knowledge level Believes she knows how implant works
Knows to remove implant after 3 years
31 (34)
90 (99)
14 (23)
60 (100)
0.12
0.42
Duration used Months, median (IQR)
Range
24 (12 - 28)
0.3 - 36
8 (6 - 12)
2 - 24
-
<0.001
Implant considered a better method  
than other options
Injectables 62 (68) 8 (13) <0.001
Oral pill 64 (70) 12 (20) <0.001
IUD 36 (40) 10 (17) 0.002
Male condoms 56 (63) 10 (16) <0.001
Female condoms 44 (49) 11 (19) <0.001
Female sterilisation 34 (38) 12 (20) 0.017
Rating of overall experience with  
the implant
Very good 30 (33) 1 (2) -
Good 37 (41) 8 (13) -
Average 11 (12) 10 (16) -
Bad 9 (10) 27 (44) -
Very bad 4 (4) 15 (25) <0.001
STIs = sexually transmitted infections; IQR = interquartile range; IUD = intrauterine device. 
*Among those who had a partner at the time. 
†Saves time, fewer clinic visits and longer duration of protection were considered indicators of method convenience.
‡Multiple-response question. 
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pills,’ with another saying ‘I don't have to stress about being in long 
queues waiting to get prevention pills, so I only come once and be stress-
free for 3 years.’ The effectiveness of the implant was also praised by 
some, especially by one woman who had previously had an unintended 
pregnancy while using DMPA. Another, a 21-year-old, spoke of how 
the contraceptive had allayed her anxiety about pregnancy: ‘Since 
I've started using it I am not worried about getting pregnant.’ Some 
enthusiasts suggested the method was especially suitable for younger 
women, with one woman saying: ‘I think if they can go to school and 
introduce it for teenage pregnancy, because it takes time to expire and 
I haven’t experienced side-effects.’ 
Side-effects among users and removers
In free-text responses, many users stated categorically that they had 
not experienced any side-effects. One woman summed this up well: 
‘For me, I haven't experienced any side-effect unlike before using 
Depo, this one it is very good to me,’ and another concurred: ‘I 
haven't had a problem, not even one, everything is just normal.’ Ten 
of the users, however, reported having had heavy bleeding, with one 
saying: ‘Although I experienced constantly bleeding, I would say it is 
not that bad.’ A similar number (13/91) of users ascribed headaches 
to implant use. One said, for example, ‘I would say it’s a good 
preventive method I have ever used, but I experience a headache 
on early days when I inserted it, but now I’m ok and I would like to 
continue using it’. These sentiments were echoed by another woman: 
‘I sometimes bleed and experience bad headache, but it disappear at 
times and it doesn’t bother my health.’ 
When asked about reasons for discontinuation, the vast majority 
of removers cited intolerable side-effects (90%). Two-thirds of 
these related to changed bleeding patterns, which were described 
as follows: ‘I was bleeding a lot, non-stop,’ or ‘I was having periods 
every day’ and ‘the bleeding I had, it was uncontrollable for 3 months.’ 
As this quote and several others suggest, women found not only 
the duration of bleeding problematic, but also the amount: 31% of 
removers said they had experienced heavy bleeding. 
Approximately a third (13/37) of the women who had had the 
implant removed for heavy or prolonged bleeding had sought advice 
from healthcare providers, and been given oral contraception for 
bleeding control. Though the medication had controlled bleeding for 
brief periods of time in some women, none reported that it provided 
long-term symptom relief. A few indicated that considerable gaps 
between bleeding intervals were also problematic, with one saying: ‘I 
haven’t experienced something bad, except I don’t see my periods now.’
Headaches were given as the reason for 44% of the removals related 
to side-effects. These were described as ‘constant headaches’ and 
‘headaches every day’. One woman said: ‘It was fine in the beginning, 
but then as the months went by it [the implant] started to cause me 
severe migraines.’ Weight gain, often linked to an increased appetite, 
accounted for 15% of removals, but weight loss was also mentioned 
by a few women.
Some women had multiple side-effects, which occurred in various 
combinations, for example: ‘Since I inserted it, I always had bleeding 
and terrible headache,’ and ‘because of heavy bleeding [my] sexual 
desires drop, it makes me sick, nausea, headaches and I will never use 
it again.’ Others reported generalised or nonspecific complaints, such 
as ‘I was always sick and I felt tired every time,’ and another woman 
attributed human emotions to the device: ‘Because it [the implant] 
doesn’t like me’.
Many side-effects were described as having diminished with time. 
One woman explained that ‘I was bleeding in the beginning after a 
month that I had inserted it, but then it stop and I have been fine 
ever since.’ For some, however, the occurrence of side-effects did not 
recede, nor were they confined to the period shortly after insertion. 
For example, one woman who had used the device for 26 months 
reported that ‘At first it was fine, but now I’m experiencing headache, 
bleeding and I’m also gaining weight, so I want to remove it now,’ and 
another recounted that ‘At first 2 years using implant I had a good 
experience, but now I am bleeding a lot and I want to remove it’. 
Complications at the site of insertion were reported by four women 
(three users and one remover). This included ongoing pain in the 
arm (‘a painful elbow on the side where implant was inserted’) and a 
rash (‘[I] recently develop some rash near the implant’). One woman 
reported that ‘[My] arm was swollen, black and painful’.
Lastly, three women had the implant removed as they wished to 
conceive, while one woman removed the implant after using it for 
2 years as she had become pregnant while using it. She then had an 
elective abortion and had an IUD inserted thereafter. 
Effects of rumours and provider attitudes 
The attitudes of others, including partners, family and community 
members, towards the implant had shaped the way that women 
perceived the method and their decision about whether to continue 
its use. A quote from a remover illustrates this well: ‘I didn't think 
it [headaches almost every day] was a problem, until I heard other 
women who have inserted it complain about the same thing.’ In 
keeping with this theme, several doubts about the implant were 
apparent, mainly concerning the effectiveness of the method: ‘I 
would like to know why you get pregnant while on it? I heard some 
rumours,’ and ‘Is it true that you can fall pregnant while using it, 
because other sister told me that you can fall pregnant?’ 
Rumours that appear to exaggerate the frequency and severity of 
side-effects were also commonly reported: ‘Why does it affect people 
so badly? I heard there are lot of side-effects,’ and ‘So many people are 
complaining about side-effects, can’t the health people do something 
to make it better?’ One woman summed this up well: ‘[The] 
perception is that most, or the large majority of women experience 
side-effects, even women who had not had any side-effects had the 
perception that most women had them.’ 
Several women were worried about potential drug interactions 
with the implant, but lacked detailed information, as illustrated by 
the question: ‘Is it true that if you are on chronic treatment is not 
good to use implant?’ In fact, three women reported concerns about 
potential interactions with antiretroviral drugs, an HIV-positive 
woman saying: ‘And I didn't have any complications, except for later 
I was told that I could get pregnant when using the Implanon while 
on ARVs [antiretrovirals]. So I had to remove it.’ Another said: ‘Now 
as I’m going to start the ARVs programme the sister who is going to 
initiate me with it said I must remove the implant because of the side-
effect.’ Finally, it is possible that negative connotations associated with 
the method had already reduced access to the implant. One woman 
asked: ‘Why they are not inserting implant anymore at the clinic? 
They refer us to other facility, my sister wanted to insert it.’ Another 
woman reported difficulties in accessing removal services, saying that 
‘I came to remove it, but they told me the nurse who was inserting 
it is not around … they refer me to [clinic X] and at [clinic X] they 
refused, they said I must go to a clinic where I inserted.’
The influence of male partners and sexual relationships
The influence of partners on implant insertion and removal varied 
considerably by partner type. Of those in a relationship, levels of 
partner consultation and agreement prior to insertion were higher 
among married (82%, 32/39) than unmarried women (42%, 40/95; 
p<0.001). Partner involvement was also higher among removers 
(64%) than users (47%; p=0.02). Interestingly, a third of users were 
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using the method without the knowledge of their partner (33%, 
27/81), while only 13% of removers had informed their partner 
of implant use (7/55; p=0.06). One user explained this practice: 
‘My partner wants more children and he doesn’t want me to use 
preventive method, so I thought implant would be good to hide that 
I’m on contraceptive.’
A number of women recounted how the implant had affected 
their sexual relationships. This mostly related to prolonged bleeding, 
with one woman in a stable relationship saying: ‘Because I was 
bleeding almost every day, so I couldn’t have sex with him because 
it felt uncomfortable,’ and another noting that ‘We couldn’t have 
sex anymore because I was always bleeding.’ Partners held strong 
views on bleeding side-effects, with one woman with a stable partner 
saying: ‘He was starting to get irritated by the fact that I was always 
sick and obviously we couldn’t have sex on a regular basis.’ One 
woman even said: ‘It was okay, but then my boyfriend told me to go 
and remove it.’ 
A few women reported that the implant had negatively affected 
their libido, with one saying: ‘I had excessive bleeding, headaches and 
I didn’t feel my boyfriend sexually.’ Vaginal dryness was also noted: 
‘My vagina was always dry so it was hard for me to sleep with my 
husband.’ Lastly, men appear to have also contributed to propagating 
misconceptions or rumours about the implant. One woman recalled 
that ‘he [her stable partner] told me that people are saying it stops 
women from having children and that one day I would [be like] those 
women that struggle to have children’.
Discussion
This study, the first evaluation of the implant introduction in SA, 
provides important insights into why women chose the method, 
their experiences with it and their reasons for discontinuation. 
Examining differences in the characteristic of users and removers, 
and the reasons underpinning their very divergent experiences, 
provides useful insights for improving implant services, especially 
pre-insertion counselling and management of side-effects. The 
findings about side-effects may appear concerning, but are similar to 
studies of removers elsewhere,[12] as are the high levels of acceptability 
among users, who commonly make up about 80% of all those who 
insert the implant.[13-16] 
The motivations for implant use were strongly tied to the method’s 
convenience, such as its long action and lack of requirement for 
adherence by the user. Reductions in clinic visits were especially 
important for women working or studying. Interestingly, convenience 
was more commonly cited as the motive for use in removers than users. 
Perhaps, if convenience is overwhelming the primary motive rather 
than factors such as contraceptive effectiveness, then women more 
readily remove it once ‘inconvenient’ effects become apparent. Women 
with motives such as contraceptive effectiveness appear to be more 
resilient in tolerating difficulties encountered. 
Rumours, based on partially accurate information, appear to have 
accrued rapidly, despite many women being very satisfied with the 
method. Both users and removers recalled how they, other women 
and healthcare providers had held very favourable views towards the 
implant when it was first introduced, but that these opinions are being 
eroded by negative perceptions around side-effects and even of a lack 
of efficacy in preventing pregnancy. These perceptions may become 
entrenched within popular culture unless they are redressed soon. 
While interactions with providers are clearly important, the 
influence of family and community in shaping women’s attitudes 
to contraceptive methods should not be underestimated. These 
groups – who were commonly the initial, but also ongoing source of 
information about the method – may promote a certain method, but 
can also rapidly undermine its use. It is promising that many women 
had negotiated implant use with their partners, the majority of whom 
apparently supported implant use, at least initially. Other women, 
however, had elected to use the device clandestinely. Men reportedly 
exerted influence over removals, especially where prolonged bleeding 
had affected sexual relations. 
The large majority (50/61, 82%) of removers had discontinued 
the implant within a year of insertion. As is consistent with studies 
elsewhere,[13,17] the principal reasons for implant removal were side-
effects, specifically intolerable bleeding for two-thirds of removers 
and headaches in almost a half. Users and removers often appeared 
to have similar side-effects. More nuanced qualitative data are needed 
to understand why some women elect to remove the implant, while 
it is retained by others with seemingly identical effects. Relationship 
status and sexual activity may explain this, at least in part. Removals 
were especially common among married or cohabiting women. In 
a long-term intimate relationship, the inconvenience of prolonged 
bleeding may be felt more than in a situation where a woman is single 
or in a casual relationship. This consideration, which has not been 
reported in several similar previous studies,[3,14] should perhaps be 
discussed with women prior to their selection of the implant. 
The topics covered in pre-insertion counselling appear to vary 
widely and require standardisation. Heightened emphasis on the 
considerable strengths of the implant may promote its uptake 
and continuation (only a quarter (29% users, and 29% removers) 
recalled being informed of the method’s remarkable effectiveness, 
for example. Aside from some reduction in effectiveness due to drug 
interactions with some drugs, the implant is as much as 180 times 
more effective than short-acting methods.[18] Even though efavirenz 
use reduces the effectiveness of the implant, by lowering levels of the 
active drug in Implanon (etonogestrel),[19,20] the implant still appears 
more effective in these patients than other contraceptive methods. 
Relative effectiveness – as well as the likelihood of side-effects – can 
be hard to convey in counselling.[21] Job aids may facilitate this, but 
some recommend simply discussing contraceptive options in order of 
effectiveness from highest (LARCs) to lowest.[22,23] This ‘LARC-first’ 
approach to counselling extends, in some settings, to LARCs being 
promoted explicitly as first-line contraception and other methods as 
second-tier.[23]
In the absence of pre-insertion counselling preparing women for side-
effects, these may be particularly alarming, leading to implant removal 
in some who otherwise may have retained it. Support, both clinical and 
psychosocial, is required when side-effects occur.[24] This would include 
providing medication to mitigate abnormal bleeding and headaches. 
Although women only ‘need’ to return every 3 years, they should 
be encouraged to attend the clinic for assistance, reassurance and 
support as needed. Counsellors had strongly emphasised the notion 
that the device ‘needs to’ or ‘should’ be used for 3 years, rather than it 
‘could’ be. Emphasis on the former may needlessly discourage uptake 
among women desiring protection for shorter periods. 
Providers require a clear policy on interactions between the implant 
and enzyme-inducing drugs, including certain ARVs.[20,25] In the 
presence of ambiguity, providers may understandably err on the side of 
caution, either by not offering implants to potentially eligible women, 
or through unnecessarily recommending implant removal.[20] 
The groups commonly targeted by implant programmes, such 
as young women, first-time contraceptive users and women 
immediately postpartum or post-abortion,[26,27] do not appear to have 
been specifically prioritised in SA. Only 15% of participants were 
aged 18 - 24, the group in SA in which  almost a third have an unmet 
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need for contraception, according to national surveys.[5,6] Low levels 
of HIV testing among the participants also reinforces long-standing 
calls for the integration of HIV and contraception services.[28]
The study has several limitations. Owing largely to deficiencies 
in record-keeping, only 20% of potentially eligible women were 
enrolled. Also, there are some notable gaps in our data. For example, 
we did not enquire whether women had experienced difficulties 
with accessing implant removal. The inclusion of many open-ended 
questions, however, allowed us to explore the data in more detail than 
would have been possible with a quantitative approach alone. Lastly, 
the diversity of the study population is a strength of the study. Views 
were gathered of women from many clinics, across both a densely 
urbanised and a semi-rural district. 
Conclusions 
While favourable views towards the implant initially drove its 
uptake, negative perceptions may now risk undermining these 
gains. Media campaigns, including visual and social media and 
patient materials addressing rumours or misinformation about the 
method, are required to reshape the negative discourse around the 
method. Implant services need to focus on counselling regarding the 
method’s advantages, especially its high effectiveness and women’s 
rapid return to fertility after discontinuation, attributes seemingly 
not highlighted during counselling. But, equally importantly, much 
greater attention during pre-insertion counselling is needed to 
ensure that women are aware of potential side-effects, particularly 
bleeding changes, enabling potential users to make an informed 
decision about whether the implant is the right method for them. 
Standardised counselling tools could assist providers to explain the 
complexities around the relative effectiveness of contraceptives, and 
side-effects. Treatment protocols could guide providers on clinical 
care for women experiencing side-effects, especially bleeding and 
headaches. Moreover, more efforts are needed to promote the implant 
among young women, those employed or studying, as well as first-
time contraceptive users. All these actions together could reverse the 
persistent decline in implant use in SA.
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